李芳菲博士教學科研部助理教授
抗腫瘤藥物研究
fangfeili@hkbu.edu.hk

李芳菲博士2007年本科畢業于中國海洋大學化學系，同年保送本校碩士研究生。2009年獲得國家留學基金委（CSC）資助赴澳大利亞新南威爾斯大學攻讀博士學位，2013年取得化學博士學位。回國後在中國科學院北京微生物所進行博士後研究。2015年加入香港浸會大學中醫藥學院進行博士後研究，2016年任職研究助理教授，2021年晉升為助理教授。
李博士的研究致力於基於適配子的創新抗癌藥物與靶向遞送系統的研發，主要包括三個方向：1）核酸適配子-小分子偶合物新型抗腫瘤藥物；2）基於核酸適配子的腫瘤免疫治療；3）腫瘤靶向的核酸適配子修飾納米顆粒藥物遞送系統。她的研究成果主要發表於Nature Communications, Biomaterials, Chemical Science, Frontiers in Immunology 等國際高水準期刊。
精選出版物Sun M, Chen Z, Wu X, Yu Y, Wang L, Lu A, Zhang G, Li F, ‘The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research’, Front. Immunol., 2021, 12: 602330. (Impact factor 7.561)
Sun M, Wu X, Yu Y, Wang L, Xie D, Zhang Z, Chen L, Lu A, Zhang G, Li F. ‘Disorders of Calcium and Phosphorus Metabolism and the Proteomics/Metabolomics-Based Research’ Front Cell Dev Biol., 2020, 8:576110. (Impact factor 6.684)
Liang C, Peng S, Li J, Lu J, Guan D, Jiang F, Lu C, Li F, He X, Zhu H, Au DWT, Yang D, Zhang BT, Lu A, Zhang G. Inhibition of osteoblastic Smurf1 promotes bone formation in mouse models of distinctive age-related osteoporosis. Nat. Commun. 2018; Aug 24;9(1):3428. doi: 10.1038/s41467-018-05974-z. (Impact factor 11.878)
Li F, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang Z-K, Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S, Zhang B-T, Lu A, Zhang G. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat. Commun. 2017; 8, 1390. (Impact factor 11.878)
Liang C, Li F, Wang L, Zhang ZK, Wang C, He B, Li J, Chen Z, Shaikh AB, Liu J, Wu X, Peng S, Dang L, Guo B, He X, Au DWT, Lu C, Zhu H, Zhang BT, Lu A, Zhang G. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials 2017; 147, 68. (Impact factor 10.273)
Li F, Gorle AK, Ranson M, Vine KL, Kinobe R, Feterl M, Warner JM, Keene FR, Collins JG, Day AI, ‘Probing the pharmacokinetics of cucurbit[7, 8 and 10]uril: and a dinuclear ruthenium antimicrobial complex encapsulated in cucurbit[10]uril.’ Org. Biomol. Chem. 2017; 15, 4172. (Impact factor 3.564)
Li F, J. G. Collins, F. R. Keene, ‘Ruthenium complexes as antimicrobial agents.’ Chem. Soc. Rev., 2015; 44, 2529-42. (Impact factor 40.443)
Li F, Harry E J, Bottomley AL, Edstein MD, Birrell GW, Woodward CE, Keene FR, Collins JG, ‘Dinuclear ruthenium(II) antimicrobial agents that selectively target polysomes in vivo’, Chem. Sci., 2014; 5, 685. (Impact factor 9.556)
Li F, Feterl M, Warner JM, Keene FR, Collins JG, ‘Dinuclear polypyridylruthenium(II) complexes: flow cytometry studies of their accumulation in bacteria and the effect on the bacterial membrane.’ J. Antimicrob. Chemother., 2013; 68, 2825. (Impact factor 5.217)
Li F, Feterl M, Warner JM, Day AI, Keene FR, Collins JG, ‘Protein binding by dinuclear polypyridyl ruthenium(II) complexes and the effect of cucurbit[10]uril encapsulation.’ Dalton Trans., 2013; 42, 8868. (Impact factor 4.099)
Li F, Weber DK, Morgan JL, Collins JG, Keene FR, ‘An approach to therapeutic agents through selective targeting of destabilised nucleic acid duplex sequences.’ Dalton Trans., 2012; 41, 6528. (Impact factor 4.099)
Li F, Feterl M, Warner JM, Collins JG, Keene FR, ‘In vitro susceptibility and cellular uptake for a new class of antimicrobial agents: dinuclear ruthenium(II) complexes.’ J. Antimicrob. Chemother., 2012; 67, 2686. (Impact factor 5.217)
Li F, Mulyana Y, Feterl M, Warner J M, Collins J G, Keene F R, ‘The antimicrobial activity of inert oligonuclear polypyridylruthenium(II) complexes against pathogenic bacteria, including MRSA’ Dalton Trans., 2011, 40(18), 5032-8. (Impact factor 4.099)
Li D, Liu J (Co-first author), Guo B, Liang C, Dang L, Lu C, He X, Cheung HY, Xu L, Lu C, He B, Liu B, Shaikh AB, Li F, Wang L, Yang Z, Au DW, Peng S, Zhang Z, Zhang BT, Pan X, Qian A, Shang P, Xiao L, Jiang B, Wong CK, Xu J, Bian Z, Liang Z, Guo DA, Zhu H, Tan W, Lu A, Zhang G. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun. 2016; 7(7): 10872. (Impact factor 11.878)
Wu X, Li F, Dang L, Liang C, Lu A, Zhang G, ‘RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies’, Front. Cell Dev. Biol.2020; doi.org/10.3389/fcell.2020.00076 (Impact factor 5.26)
Wang L, Li F, Dang L, Liang C, Wang C, He B, Liu J, Li D, Wu X, Xu X, Lu A, Zhang G, ‘In Vivo Delivery Systems for Therapeutic Genome Editing.’ Int J Mol Sci. 2016; 17, 626. (Impact factor 3.687)
Shaikh AB, Li F, Li M, He B, He X, Chen G, Guo B, Li D, Jiang F, Dang L, Zheng S, Liang C, Liu J, Lu C, Liu B, Lu J, Wang L, Lu A, Zhang G. ‘Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.’ Int J Mol Sci. 2016, 17, 506. (Impact factor 3.687)
Pandrala M, Li F, Feterl M, Mulyana Y, Warner JM, Wallace L, Keene FR, Collins J G, ‘Chlorido-containing ruthenium(II) and iridium(III) complexes as antimicrobial agents.’ Dalton Trans., 2013; 42, 4686. (Impact factor 4.099)
Pandrala M, Li F, Wallace L, Steel PJ, Moore II B, Autschbach J, Collins JG, Keene FR, ‘Iridium(III) Complexes containing 1,10-Phenanthroline and Derivatives – Synthetic, Stereochemical and Structural Studies, and their Antimicrobial Activity.’ Aust. J. Chem., 2013; 66, 1065. (Impact factor 1.427)